Orion宣布：合作伙伴Tenax的临床试验未达主要终点

投资观察08-10

Orion Oyj 旗下授权合作伙伴Tenax Therapeutics的3期临床试验未能达到其主要终点。该试验是一项针对口服左西孟旦在射血分数保留的心力衰竭合并肺动脉高压（PH-HFPEF）患者中的3期临床研究。Tenax计划向美国食品药品监督管理局申请会议，讨论修订当前左西孟旦用于治疗PH-HFPEF的注册性开发方案。同时，Tenax也将寻求欧洲药品管理局的平行科学咨询意见。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1141240687?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-10 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141240687","market":"us","top_or_hot":-1,"title":"Orion宣布：合作伙伴Tenax的临床试验未达主要终点","media":"投资观察","content":"<p>Orion Oyj 旗下授权合作伙伴Tenax Therapeutics的3期临床试验未能达到其主要终点。该试验是一项针对口服左西孟旦在射血分数保留的心力衰竭合并肺动脉高压（PH-HFPEF）患者中的3期临床研究。Tenax计划向美国食品药品监督管理局申请会议，讨论修订当前左西孟旦用于治疗PH-HFPEF的注册性开发方案。同时，Tenax也将寻求欧洲药品管理局的平行科学咨询意见。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orion宣布：合作伙伴Tenax的临床试验未达主要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrion宣布：合作伙伴Tenax的临床试验未达主要终点\n</h2>\n\n<h4 class=\"meta\">\n\n2026-08-10 19:23 北京时间&nbsp;&nbsp;&nbsp;<strong>投资观察</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orion Oyj 旗下授权合作伙伴Tenax Therapeutics的3期临床试验未能达到其主要终点。该试验是一项针对口服左西孟旦在射血分数保留的心力衰竭合并肺动脉高压（PH-HFPEF）患者中的3期临床研究。Tenax计划向美国食品药品监督管理局申请会议，讨论修订当前左西孟旦用于治疗PH-HFPEF的注册性开发方案。同时，Tenax也将寻求欧洲药品管理局的平行科学咨询意见。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TENX","symbol_name":"Tenax Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1141240687","we_media_id":"1076224072","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141240687","pubTimestamp":1786361022,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"投资观察","introduction":"关注海外资本市场一手动态","home_visible":1,"id":"1076224072","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Orion Oyj 旗下授权合作伙伴Tenax Therapeutics的3期临床试验未能达到其主要终点。该试验是一项针对口服左西孟旦在射血分数保留的心力衰竭合并肺动脉高压（PH-HFPEF）患者中的3期临床研究。Tenax计划向美国食品药品监督管理局申请会议，讨论修订当前左西孟旦用于治疗PH-HFPEF的注册性开发方案。同时，Tenax也将寻求欧洲药品管理局的平行科学咨询意见。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"TENX":"Tenax Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Orion Announces: Partner Tenax's Clinical Trial Misses Primary Endpoint","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TENX":1},"content_text":"Orion Oyj 旗下授权合作伙伴Tenax Therapeutics的3期临床试验未能达到其主要终点。该试验是一项针对口服左西孟旦在射血分数保留的心力衰竭合并肺动脉高压（PH-HFPEF）患者中的3期临床研究。Tenax计划向美国食品药品监督管理局申请会议，讨论修订当前左西孟旦用于治疗PH-HFPEF的注册性开发方案。同时，Tenax也将寻求欧洲药品管理局的平行科学咨询意见。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141240687","isCrawlerRequest":true}